Latest Non Dilutive Funding News

Felix Gold made substantial progress on its proposed Alaska antimony mine and US refinery during the September quarter, including 80 drill holes and pilot-scale production of cast antimony metal. The progress came at a cost: cash fell to A$1.267 million, equal to an estimated 0.1 quarters of funding on the quarter’s reported outgoings.

Chariot Resources has moved its Nigerian lithium strategy forward with licence approvals, geological mapping and a proposed partner-funded drilling and offtake program. But with A$600,000 in cash, A$3.19 million of borrowings and an estimated 0.75 quarters of funding, the next phase depends on securing more capital.

Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.

Desert Metals has agreed to sell its 80% stake in Tengrela South to Waraba Gold for up to A$5 million, giving the cash-poor explorer a potential non-dilutive funding bridge. The company will redirect its focus to drilling the undrilled Nyan gold corridor and exploring new Agboville permits in Côte d’Ivoire.

Bayan Mining and Minerals completed maiden drilling at Desert Star and reported encouraging early yttrium processing results, but ended September with A$865,000 in cash and only 1.44 quarters of funding at the reported spending rate. The company says future capital raisings are expected to support ongoing exploration and development.

Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.

OzAurum Resources has strengthened the technical case for a low-capex heap leach operation at Mulgabbie North, with column testing delivering up to 95% gold recovery. But the project’s next phase is now tied to a capital raise after cash fell to A$542,000, equivalent to just 0.8 quarters of estimated funding.

Vital Metals has extended rare earth and niobium mineralisation beyond Tardiff’s 192.7 million tonne resource envelope, strengthening the case for an updated resource estimate and pre-feasibility study. But the ASX-listed developer ended September with A$2.4 million in cash, equivalent to just 1.87 quarters of funding before higher arbitration costs.

Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.

Anson Resources has applied to establish a Utah Public Infrastructure District that could issue bonds backed by future tax differential revenues for infrastructure at its Green River lithium project. The proposal offers a possible non-dilutive funding route, but no bonds have been approved, sized or arranged.

Lightning Minerals has secured A$100,000 in non-dilutive cash and a funded 400-metre drilling commitment by granting Kincora Copper a nine-month option over six Lachlan Fold Belt licences. The deal could deliver another A$350,000, but only if Kincora exercises the option, approvals are obtained and a key tenement is renewed.

EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.